Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NWBO
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) May 29, 2023
Of course you are excited Mike. 👍🏻 pic.twitter.com/Ax4JM6qrpE
UK-Swiss Cell & Gene Therapy Exchange in Zurich.
May 24, 2023
Yesterday the Autolomous team participated in the UK-Swiss Cell & Gene Therapy Exchange. The morning's session "The Great CGT Challenge" involved discussing challenges and innovative solutions as an imaginary CGT company. Thank you for this thought provoking activity! pic.twitter.com/ZZxChung6r
— Autolomous (@autolomous) May 25, 2023
British and Swiss Cell & Gene Therapy experts are meeting today in Zurich for a third exchange organised by the British Embassy and opened by Ambassador @JamesWSquire.
— UK Embassy Berne 🇬🇧🇨🇭🇱🇮 (@UKEmbassyBerne) May 24, 2023
A packed day with discussions & networking, to leverage 🇬🇧 & 🇨🇭’s excellent CGT ecosystems & tackle challenges. https://t.co/CJBlBYDM2M
Researchers found that glioblastoma cells steal mitochondria, the power plants of our cells, from other cells in the central nervous system.
It seems that stealing mitochondria from neighboring normal cells help these transformed glioblastoma cells to ramp up their growth.
dstock07734,
I think it’s Dr. Catharine (Clark) Young from the White House Office of Science and Technology Policy - Cancer Moonshot.
Behind the scenes with Dr.@catgyoung from the White House Cancer Moonshot office, talking about the goals of the cancer moonshot. #globalhealthcatalyst #cancermoonshot #healthcareblindspots pic.twitter.com/tpHZGdQ5XW
— Vivian Kobusingye Birchall (@VivianBirchall) May 9, 2023
Agreed! See picture.(Lady in the middle)
Very productive @WHOSTP #CancerMoonshot forum on #GBM and #DIPG. Sharing a clear vision: Now is the moment to leverage progress in neuroscience, immunology & oncology, to work together in interdisciplinary academic-industry-advocate teams to #EndBrainCancerAsWeKnowIt https://t.co/NqG79eiLAO pic.twitter.com/V30wcMdfBq
— Michelle Monje🎗️ (@michelle_monje) May 27, 2023
Zadie420,
Sincere condolences on the passing of your friend.
Letter
First published online May 26, 2023
DCvax: A promising advancement in oncology for the treatment of glioblastoma.
Authors: Areeba Fareed, Samia Rohail, Alishba Adnan, Abdul Moiz Khan
Dear Editor,
Glioblastoma is a malignant neoplasm of the central nervous system that arises from glial cells, primarily astrocyctes and is characterized by poorly differentiated, fusiform, round or pleomorphic astrocyctic cells with marked nuclear atypical and brisk mitotic activity.1
Despite advances in early diagnosis and comprehensive treatments, there is nearly 100% recurrence rate and dismal patient survival.2 According to researchers, more than 13,000 Americans are diagnosed with Glioblastoma annually, causing significant morbidity and mortality. There has been no cure for Glioblastoma so far.3 Treatment options often include surgical removal of the tumor followed by concomitant radiation and adjuvant temozolomide TMZ chemotherapy which has been the standard of care for glioblastoma since decades, but exposure to high doses of ionizing radiation is a well-known exogenous risk factor for glioblastoma. The inability to cross the BBB is the major obstacle in achieving remission after surgical resection followed by chemotherapy and radiation.4 As a result, glioblastoma typically recurs within six to 8 months and the survival rate is generally less than 5%.2 Despite the development of novel, complex, multidisciplinary, and targeted therapies the outcome for patients remains almost universally lethal.5 Therefore, the need for effective treatment is undeniable.
For this reason, it has been a priority area in cancer research. Recently, US biotech company Northwest Biotherapeutics has developed a brain cancer vaccine, called DCVax, which is designed to help patients' immune system to target their tumors that may prolong their life by months or, in some cases, years.5 Thus, opening a door for the development of innovative therapy for targeting glioblastoma. The vaccine is created for each patient individually by isolating dendritic cells, from their blood which is then primed with biomarkers from a sample of the patient’s tumor.6 Dendritic cells present tumor antigens to the immune system, prime T cells, and mobilize antitumor responses.6
To evaluate the safety of the vaccine and its impact on survival time in patients with Glioblastoma, a phase 3 randomized control trial was conducted.7 In this trial, 348 patients newly diagnosed with Glioblastoma were tested at King’s College Hospital and other centers around the world for 8 years.7 Patients had surgery to remove their tumors as much as possible, followed by radiation and chemotherapy as the standard treatment for Glioblastoma.7 Among these patients, two out of three were treated with the vaccine, DCVax-L, with the remaining one-third receiving a placebo.7 The astonishing result of the trial has shown that newly diagnosed patients who received the vaccine survived for 19.3 months compared to 16.5 months for those who received a placebo.8 Overall 13% of all trial participants treated with DCVax lived more than 5 years after diagnosis compared with 5.7% in the comparison group who did so.8 Moreover, this is the first time in 17 years that such a significant result has been achieved in a Phase 3 trial of a systemic treatment for newly diagnosed Glioblastoma, and it’s the first treatment in 27 years for patients with GBM recurrence.9
Thus, this development represents a major step forward in our efforts to combat this devastating disease. Based on the findings of the trials evaluating the drug’s efficacy, it has the potential to improve the quality of life for patients, especially for the elderly and those unable to have surgery. A global clinical trial has concluded that the DCVax is the world’s first vaccine to treat deadly cancerous brain tumors that could help patients to live for years.9 This breakthrough could benefit 2500 people a year in the UK being diagnosed with Glioblastoma.9 It has also been shown that this therapy can be used to treat cancers other than Glioblastoma.9
However, due to high recurrence rate and lethal outcomes, the treatment of gliblastoma has seen significant transformation, switching from an aggressive surgical strategy to a more cautious one. The endorsement of the vaccine is a commendable achievement, and it demonstrates the unwavering commitment of researchers and healthcare professionals to discovering effective treatments for such lethal disease. Furthermore, vaccine may enhance the quality of life of a patient and provides a new hope for patients and their families Thus, it is crucial that we continue to support research into Glioblastoma and the development of novel treatments so that we can envision a future where this disease is eradicated.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
https://journals.sagepub.com/doi/10.1177/20363613231179541
Today Laura makes her final contribution to the fight against #glioblastoma by donating her brain to medical research
— shitscaredmum (@shitscaredmum) May 26, 2023
Laura was passionate about improving treatment so that other families don’t go through the same pain as us#BeMoreLaura@ICR_London @BrainTumourOrg @ourbrainbank pic.twitter.com/3t6Q2BNNDx
I agree. A little imagination is needed. I'll give you a lock of blond hair and a green jacket.
Beyond excited to be @WhiteHouse today #cancermoonshot. Thank you @DrAlfredYung @PamSharmaMDPhD @boehmjesse @MDAndersonNews @break_cancer @POTUS @VPuduvalli @nathalieagar #GBM #DIPG #endcancer pic.twitter.com/VpK9aTqC32
— Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE (@BettyKimLab) May 25, 2023
antihama,
Here's a picture of the audience.
At the very back you see the blonde woman (green jacket) next to Anabella Aspiras, Assistant Director, Cancer Moonshot Engagement.
Inspired time at White House with @WHOSTP and @theNCI Moonshot teams - let’s create a vision for a future of GBM that patients deserve…and implement it by working as one national team! @corrie_painter @BettyKimLab @Bando_Lab @adrienne_boire @TabarViviane @VPuduvalli Nat Agar pic.twitter.com/L1Wcze3pHk
— Jesse Boehm (@boehmjesse) May 25, 2023
attilathehunt,
I think it's someone from the White House "CancerMoonshot" administration.
— Pratiti (Mimi) Bandopadhayay (@Bando_Lab) May 25, 2023
Listening to moving opening words at the @WhiteHouse #CancerMoonshot Brain Tumor Forum by @LisaWardspeakup #DIPGwontwait #EndDIPG #EndDMG #EndGBM pic.twitter.com/qkBizFMHmh
— Nick Vitanza (@VitanzaNick) May 25, 2023
Great combined metaphor from @adamhayden of @NBTStweets and @D_Carnival of @WHOSTP - patients and their caregivers are already doing something extraordinary and courageous by living with this disease. They are on the moon already. Our job is to rescue them. Let's bring them home
— Edjah Nduom, MD (he/him) (@EKNduom) May 25, 2023
I’m so sorry to read this. My thoughts are with the entire family. Sending all so much love.
I'm heartbroken to share the news that we lost our beautiful Laura in the early hours of this morning.
— shitscaredmum (@shitscaredmum) May 22, 2023
She was fierce & tenacious to the end & it was truly the honour of my life to be her mum.
We are devastated at the thought of life without our girl, she was a force of nature💔 pic.twitter.com/8nQvIZZ4zh
I don't know. For the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS higher than 1, the recommended dose of KEYTRUDA is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.
dstock07734,
It was on a slide on October 26, 2022.
That was at the end of 2014. And then came the summer of 2015.....
dstock07734,
anti-PD1= Pembrolizumab 400 mg q 6 weeks.
Rh2022,
Linda Powers’ Speech Transcript at the Oppenheimer 25th Annual Health Conference on 12-10-14.
sentiment,
I agree.
.
Feb.2020. Shenell is now living 51 glorious months after being diagnosed with GBM.
https://www.instagram.com/p/Coa2fESK0qB/
https://www.facebook.com/photo.php?fbid=10221078017250630&set=pcb.10221078018690666&type=3&theater
jm100,
Today, Dr. David W. Andrews, an Imvax co-founder and Chief Medical Officer spoke about " a Phase 2b Study of IGV -001 in Newly Diagnosed Glioblastoma" here;
Plus Therapeutics to present at EBCI's virtual educational event this Friday at 12 pm PT / 3 pm ET.
— Plus Therapeutics (Nasdaq: PSTV) (@plustxinc) May 15, 2023
Register now: https://t.co/Jq67TondMV#btsm #NIH #clinicaltrial #gbm #glioblastoma #neurosurgery #nuclearmedicine #oncology #raredisease #targeted #radiation #therapy https://t.co/IncldMqkdO pic.twitter.com/0PsWbIUXQp
ATLnsider,
I ask Leia Nghiemphu,
Confirmation that current combo Clinical Trial of DC vaccine + poly-ICLC + PD-1 mAb is in Pase 2. (Window of Opportunity Trial)
Min.54
2023 UCLA Brain Tumor Conference : Updates in Experimental Therapies by Leia Nghiemphu MD
Professor of Clinical Neurology
UCLA Medical Center (Ronald Reagan)
http://events.provideriq.com/Event.aspx?i=840&y=cc0ad4ce-a347-4734-976c-40ad753ada03
Thanks for the full text, dstock7734!
Thank you for sharing pgsd! Much, much appreciated!
Thanks pgsd.
I'm curious but how did you get the full text of the reply?
Thanks pgsd!
Do you have access to this :https://jamanetwork.com/journals/jamaoncology/article-abstract/2805079?resultClick=1
Comment & Response
May 18, 2023
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma
Jacob J. Mandel, MD1; John F. de Groot, MD2
Author Affiliations
1Department of Neurology and Neurosurgery, Baylor College of Medicine, Houston, Texas
2The University of California, San Francisco
JAMA Oncol. Published online May 18, 2023. doi:10.1001/jamaoncol.2023.1066
Comment & Response
May 18, 2023
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma—Reply
Linda M. Liau, MD, PhD; Keyoumars Ashkan, MD; Marnix L. Bosch, PhD
JAMA Oncol. Published online May 18, 2023. doi:10.1001/jamaoncol.2023.1072
Agreed.
I said:
Northwest Biotherapeutics is listed as a sponsor here. Unfortunately no presentation.
Plus Therapeutics to present at EBCI's virtual educational event this Friday at 12 pm PT / 3 pm ET.
— Plus Therapeutics (Nasdaq: PSTV) (@plustxinc) May 15, 2023
Register now: https://t.co/Jq67TondMV#btsm #NIH #clinicaltrial #gbm #glioblastoma #neurosurgery #nuclearmedicine #oncology #raredisease #targeted #radiation #therapy https://t.co/IncldMqkdO pic.twitter.com/0PsWbIUXQp
ATLnsider,
Poly-ICLC is used along with DCVax-L in this combo trial since last summer 2022, IMO. (Evidence: Linda Liau's presentation on Oct.26, 2022)
The first 20-23 patients enrolled between Jan.2020 - May 2022 did not receive Poly-iclc, IMO.
Min.32.40s
I wrote::
Lots of media attention today for the results of a Phase 1/2 clinical trial investigating the safety and effectiveness of a novel therapy that combines the injection of an oncolytic virus – a virus that targets and kills cancer cells – directly into the tumor, with intravenous immunotherapy. (Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial)
The results, published in Nature Medicine, show that this combination therapy is safe, well tolerated and prolongs patient survival. The therapy had no major unexpected adverse effects and yielded a median survival of 12.5 months—considerably longer than the six to eight months typically seen with existing therapies.
The patients in the trial did not have tumor resection at recurrence – only injection of the virus through a small hole and a purpose-built catheter. Then, patients received an anti-PD-1 antibody intravenously, every three weeks, starting one week after surgery.
A new paper published in @NatureMedicine by Drs. @gelarehzadeh and @FarshadNassiri @UHN @uoftmedicine using a novel combination approach to #glioblastoma treatment shows promise, extending survival.
— Krembil Brain Institute (@KBI_UHN) May 15, 2023
Learn more: https://t.co/PnmbUzfD8C#BrainTumorAwarenessMonth #Braintumor pic.twitter.com/fxkXgE2BK4
Flipper44,
I think LL uses poly-iclc to get those results.
Wednesday, October 26, 2022
“The Promise of Immunotherapy for Treatment of Glioblastoma”
Linda Liau:
Thanks for sharing ATLnsider. Good info!
hope4patients,
I'm so sorry. It is heartbreaking and incredibly cruel.
I’ve followed Laura’s journey with hope and admiration. Laura, Nicola, Mark and Gracie are all amazing.
Sending love and strength to Laura and all of the family.